Savolitinib Plus Osimertinib: A Promising Oral Combination for MET-Driven Resistance in EGFR-Mutated Advanced NSCLC – Insights from the SAVANNAH Phase II Study

Highlights

• MET-driven resistance is a frequent mechanism after first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (NSCLC).
• Savolitinib plus osimertinib achieved an objective response rate (ORR) exceeding 55% in patients with high MET overexpression/amplification post-osimertinib.
• The combination showed a median progression-free survival (PFS) of 7.4–7.5 months and was generally well tolerated.
• This regimen may establish a new oral standard for targeting MET-driven resistance following EGFR TKI therapy.

Study Background and Disease Burden